NCT04686760

Brief Summary

In current analysis moderate to severely ill Covid-19 infected patients will be nebulized with nitroglycerin, and they will be compared with the standard nebulization

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
278

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Nov 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 15, 2020

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

December 24, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

December 29, 2020

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 15, 2021

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 15, 2022

Completed
Last Updated

May 18, 2022

Status Verified

May 1, 2022

Enrollment Period

1.1 years

First QC Date

December 24, 2020

Last Update Submit

May 16, 2022

Conditions

Corona Virus Infection

Outcome Measures

Primary Outcomes (2)

  • ratio of partial pressure of oxygen in arterial blood to fraction of inhaled oxygen

    5-7 days

  • Oxygen demand

    5-7 days

Secondary Outcomes (1)

  • Duration of hospital stay

    15 days

Study Arms (2)

Nitroglycerin solution

EXPERIMENTAL
Drug: Nitroglycerin

standard solution

NO INTERVENTION

Interventions

NitroglycerinDRUG

2 mg/ml solution of nitroglycerin used for nebulization four hourly

Nitroglycerin solution

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosed admitted cases of Covid-19 degree of illness should be moderate to severe both male and female every age group

You may not qualify if:

  • allergic to nitroglycerin sudden drop in blood pressure not given consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Bahria Town International Hospital

Lahore, Punjab Province, 54000, Pakistan

Location

MeSH Terms

Conditions

Coronavirus Infections

Interventions

Nitroglycerin

Condition Hierarchy (Ancestors)

Coronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsVirus DiseasesInfections

Intervention Hierarchy (Ancestors)

Nitro CompoundsOrganic Chemicals

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

December 24, 2020

First Posted

December 29, 2020

Study Start

November 15, 2020

Primary Completion

December 15, 2021

Study Completion

March 15, 2022

Last Updated

May 18, 2022

Record last verified: 2022-05

Locations

PA(1)